Zobrazeno 1 - 10
of 159
pro vyhledávání: '"Amélie, Anota"'
Autor:
Micha J. Pilz, Fanny L.C. Loth, Sandra Nolte, Anna M.M. Thurner, Eva-Maria Gamper, Amélie Anota, Gregor Liegl, Johannes M. Giesinger, on behalf of the EORTC Quality of Life Group
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 8, Iss 1, Pp 1-10 (2024)
Abstract Background General population normative values for the widely used health-related quality of life (HRQoL) measure EORTC QLQ-C30 support the interpretation of trial results and HRQoL of patients in clinical practice. Here, we provide sex-, ag
Externí odkaz:
https://doaj.org/article/9a32ec4a91b5485c956b5b9e626c6bbd
Autor:
Hwayoung Noh, Amélie Anota, Rodolf Mongondry, Renaud Meyrand, Carmen Dupuis, Camille Schiffler, Philippe Marijnen, Sabina Rinaldi, Joel Lachuer, Pekka Keski-Rahkonen, Marc J Gunter, Aude Fléchon, Béatrice Fervers, Olivia Pérol
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-15 (2024)
Abstract Background Testicular germ cell tumours (TGCTs) are the most common malignancy in men aged 15–40 years, with increasing incidence worldwide. About 33 ~ 50% of the patients present with metastatic disease at diagnosis. TGCT survivors experi
Externí odkaz:
https://doaj.org/article/fa667221073545d7a7c16b4f0698925a
Autor:
Hugo Larose, Myrto Lee, Jens Grueger, Amélie Anota, Nicolas Naïditch, Bruno Falissard, Mario Di Palma, Olivier Chassany, Laura Khalfallah-Neelz, Sarah Palazuelos-Muñoz, Aymeric Tetafort
Publikováno v:
Health Research Policy and Systems, Vol 21, Iss 1, Pp 1-12 (2023)
Abstract Objectives Patient’s health-related quality of life (HRQoL) is an important outcome measure that is considered by many payers and health technology assessment (HTA) bodies in the evaluation of treatments. We aimed to identify opportunities
Externí odkaz:
https://doaj.org/article/fc9bb172dbd546d6bf1e7b04e9e31049
Autor:
Alya Perthus, Fanny Colin, Emilie Charton, Amélie Anota, Faustine Lhomme, Guillaume Manson, Sophie De Guibert, Pierre Daufresne, Adeline Bellec, Laetitia Le Bars, Sandra De Barros, Loïc Ysebaert, Marianne Merceur, Mélanie Cogné, Thierry Lamy De La Chapelle, Roch Houot, Aline Moignet
Publikováno v:
HemaSphere, Vol 8, Iss 5, Pp n/a-n/a (2024)
Abstract Chimeric antigen receptor T cells (CAR T cells) can induce prolonged remission in a substantial subset of patients with relapse/refractory lymphoma. However, little is known about patients' life after CAR T‐cell therapy. We prospectively a
Externí odkaz:
https://doaj.org/article/ea3c47d1b62242edb5d04dee07ef3e44
Autor:
Emmanuelle Tchernonog, Aline Moignet, Amélie Anota, Sophie Bernard, Guy Bouguet, Fanny Colin, Catherine Rioufol, Loïc Ysebaert, Emmanuel Gyan
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Chimeric antigen receptor (CAR) T-cell therapy has transformed the care of patients with relapsed/refractory B-cell derived hematologic malignancies. To date, six CAR T-cell therapies, targeting either CD19 or B-cell maturation antigen, have received
Externí odkaz:
https://doaj.org/article/ccca91ceeb7e41c187522d6681e708ea
Autor:
Anja Tüchler, Antoine De Pauw, Corinna Ernst, Amélie Anota, Inge M.M. Lakeman, Julia Dick, Nienke van der Stoep, Christi J. van Asperen, Monika Maringa, Natalie Herold, Britta Blümcke, Robert Remy, Anke Westerhoff, Denise J. Stommel-Jenner, Eléonore Frouin, Lisa Richters, Lisa Golmard, Nadine Kütting, Chrystelle Colas, Barbara Wappenschmidt, Kerstin Rhiem, Peter Devilee, Dominique Stoppa-Lyonnet, Rita K. Schmutzler, Eric Hahnen
Publikováno v:
Breast, Vol 73, Iss , Pp 103615- (2024)
Background: Breast cancer (BC) risk prediction models consider cancer family history (FH) and germline pathogenic variants (PVs) in risk genes. It remains elusive to what extent complementation with polygenic risk score (PRS) and non-genetic risk fac
Externí odkaz:
https://doaj.org/article/f91dd96772b24b38a3d25235b52f3750
Autor:
Astrid Pozet, Sophie Darnis, Magalie Bonnet, Aurélia Meurisse, Tienhan Sandrine Dabakuyo-Yonli, Catherine Lejeune, Philippe Fagnoni, Maryse Gaimard, Patrick Manckoundia, Clémence Quibel, Mélanie Marchand, Amélie Anota, Virginie Nerich
Publikováno v:
International Journal of Public Health, Vol 68 (2023)
Objectives: To assess health-related quality of life (QoL) in caregivers of elderly patients with chronic disabilities receiving, or not receiving, social worker support.Methods: This multicenter open-label randomized study assigned caregivers to rec
Externí odkaz:
https://doaj.org/article/18f0bd893afa48028483948207bcc836
Autor:
Geertruida H De Bock, Delphine Maucort-Boulch, Clémence Leyrat, Amélie Anota, Stephane Dalle, Susana Puig, Marie Préau, Mohammad S Jalali, Marie-Jose Kersten, Martijn GH van Oijen, Mathieu Fauvernier, Petra C. Vinke, Marc Combalia, Anne Mea Spanjaart, Maria Gomes da Silva, Aurore Fouda Essongue, Aurélie Rabier, Myriam Pannard, Amal Elgammal, Mike Papazoglou, Mohand-Said Hacid, Catherine Rioufol, Erick Suazo-Zepeda, Ananya Malhotra, Emmanuel Coquery, Elsa Coz
Publikováno v:
BMJ Open, Vol 13, Iss 4 (2023)
Introduction Immunotherapies, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy, have significantly improved the clinical outcomes of various malignancies. However, they also cause immune-related adverse events (irAEs)
Externí odkaz:
https://doaj.org/article/f0459fb57ecf4fbf88aa688bc3bf3ad3
Autor:
Jerome Desramé, Nathalie Baize, Amélie Anota, Kamel Laribi, Laetitia Stefani, Salim Hjiej, Ekatérina Nabirotchkina, Laurent Zelek, Sylvain Choquet
Publikováno v:
Cancer Treatment and Research Communications, Vol 37, Iss , Pp 100781- (2023)
Purpose: Available tools to measure fatigue and health-related quality of life (HRQoL) in cancer patients are often difficult to use in clinical practice. The fatigue visual analogue scale (VAS) provides a simple method to assess fatigue. This study
Externí odkaz:
https://doaj.org/article/28c5e22700fc4cbe9d46f15f71768239
Autor:
Anne Brédart, Antoine De Pauw, Amélie Anota, Anja Tüchler, Julia Dick, Anita Müller, Jean-Luc Kop, Kerstin Rhiem, Rita Schmutzler, Peter Devilee, Dominique Stoppa-Lyonnet, Sylvie Dolbeault
Publikováno v:
Breast, Vol 60, Iss , Pp 38-44 (2021)
Objectives: Comprehensive breast cancer (BC) risk models integrating effects of genetic (GRF) and non-genetic risk factors (NGRF) may refine BC prevention recommendations. We explored the perceived information received on BC risk factors, and related
Externí odkaz:
https://doaj.org/article/67907232a77444e2a89bac4928431e8b